NCT Number |
Title |
Conditions |
Interventions |
Sponsor/Collaborators |
Phases |
NCT03315182 |
Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB |
Mucopolysaccharidosis
Type 3 B |
Biological: rAAV9.CMV.hNAGLU |
Kevin Flanigan|Abeona Therapeutics, Inc|Nationwide Children's Hospital |
Phase 1
Phase 2 |
NCT03315078 |
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency |
X-Linked Combined Immunodeficiency Diseases |
Biological: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1¥á-h¥ãc-OPT|Drug: Palifermin|Drug: Busulfan |
National Institute of Allergy and Infectious Diseases (NIAID) |
Phase 1
Phase 2 |
NCT03311503 |
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning |
Severe Combined Immunodeficiency, X Linked|Gene Therapy |
Biological: autologous CD34+ cell transduced with G2SCID vector |
David Williams|University of California, Los Angeles|Boston Children¡¯s Hospital |
Phase 1
Phase 2 |
NCT03317899 |
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma |
Non-Hodgkin's Lymphoma|Multiple Myeloma |
Procedure: Hematopoietic Cell Transplantation|Drug: Tbo-filgrastim |
Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Phase 2 |
NCT03316599 |
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer |
Pancreatic Cancer |
Drug: Gemcitabine|Drug: Nab-paclitaxel|Drug: Ficlatuzumab |
Dana-Farber Cancer Institute|AVEO Pharmaceuticals, Inc. |
Phase 1 |
NCT03316586 |
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer |
Breast Cancer |
Drug: Nivolumab|Drug: Cabozantinib |
Dana-Farber Cancer Institute|Bristol-Myers Squibb|Exelixis |
Phase 2 |
NCT03315871 |
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer |
Prostate Cancer |
Biological: PROSTVAC-V|Biological: PROSTVAC-F|Drug: MSB0011359C (M7824)|Biological: CV301 |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Phase 2 |
NCT03315026 |
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis |
Multiple Myeloma|AL Amyloidosis |
Drug: Siltuximab|Behavioral: The M.D. Anderson Symptom Inventory (MDASI) |
Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC |
Phase 2 |
NCT03311828 |
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma |
Recurrent Plasma Cell Myeloma |
Biological: Daratumumab|Drug: Imaging Agent|Procedure: Positron Emission Tomography |
City of Hope Medical Center |
Phase 1 |
NCT03316573 |
A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas |
Lymphoma |
Drug: Pembrolizumab |
Dana-Farber Cancer Institute|Merck Sharp & Dohme Corp. |
Phase 2 |
NCT03314181 |
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma |
Cancer - Multiple Myeloma |
Drug: Venetoclax|Drug: Placebo|Drug: Daratumumab|Drug: Bortezomib|Drug: Dexamethasone |
AbbVie|Janssen Research & Development, LLC |
Phase 2 |
NCT03318315 |
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 |
Avian Influenza|Influenza|Influenza Immunisation |
Drug: AS03|Biological: Inactivated influenza H7N9 vaccine|Biological: Influenza Virus Quadrivalent Inactivated Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
Phase 2 |
NCT03313050 |
A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age |
Pneumococcal Infections |
Biological: Multivalent|Biological: Tdap|Biological: polysaccharide |
Pfizer |
Phase 1 |
NCT03316560 |
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR-ORF15 Mutations |
X-Linked Retinitis Pigmentosa |
Biological: rAAV2tYF-GRK1-RPGR |
Applied Genetic Technologies Corp |
Phase 1
Phase 2 |
NCT03313037 |
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age |
Pneumococcal Infections |
Biological: Multivalent|Biological: Prevnar 13|Biological: PPSV23|Other: Saline |
Pfizer |
Phase 2 |
NCT03312231 |
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly |
Avian Influenza|Influenza Immunisation |
Drug: AS03|Biological: Inactivated influenza H7N9 vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
Phase 2 |
NCT03313778 |
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors |
Solid Tumors |
Biological: mRNA-4157|Biological: Pembrolizumab |
Moderna Therapeutics|Merck Sharp & Dohme Corp. |
Phase 1 |
NCT03314662 |
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults |
Influenza, Human |
Biological: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|Biological: Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)|Biological: MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2) |
Seqirus |
Phase 3 |